Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.

Trial Profile

Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Interferon beta-1a (Primary) ; Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2016 This trial was completed in Czech Republic (end date: 2015-01-19), according to European Clinical Trials Database.
    • 17 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top